Aiforia Technologies Plc announces the CE-IVD marking of the Aiforia® Clinical AI Model for Prostate Cancer; Gleason Grade Groups. This latest regulatory certification brings Aiforia’s portfolio of AI-powered diagnostic tools to a total of 5...

Jan 5, 2022 - Combining robotic-assisted bronchoscopy with rapid on-site evaluation by cytopathologists enables cancer evaluation and diagnosis in one procedure New technologies are making it possible to both collect a tissue biopsy and...

Aiforia announces the CE-IVD mark of its Aiforia® Clinical AI Model for Lung Cancer; PD-L1 for assisting pathologists in the fast and accurate primary diagnosis of lung cancer. This latest AI model expands Aiforia’s portfolio of clinical...

Diagnosing pathological cancer is often a challenge, even for the most skilled clinicians. Many forms of cancer do not exhibit noticeable symptoms until the infection has progressed too far to treat effectively. Monoclonal antibodies are...

Financing to accelerate Aiforia’s development and continuing expansion of AI solutions for image analysis in clinical diagnostics and preclinical pathology. HELSINKI, Sept 16, 2021 -- Aiforia, a software company providing AI-based solutions...

Swifter discovery can improve life expectancy A longer life expectancy goes hand in hand with the risk of cancer. The Hamburg-based Mindpeak is developing artificial intelligence to help pathologists diagnose cancer swiftly. Until now,...